The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer

  • Authors:
    • Miguel Muñoz
    • Ana González-Ortega
    • Manuel Vicente Salinas-Martín
    • Andrés Carranza
    • Susana Garcia-Recio
    • Vanessa Almendro
    • Rafael Coveñas
  • View Affiliations

  • Published online on: July 28, 2014     https://doi.org/10.3892/ijo.2014.2565
  • Pages: 1658-1672
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The substance P (SP)/neurokinin (NK)-1 receptor system plays an important role in the development of cancer. No in-depth studies of the involvement of this system in breast cancer (BC) have been carried out, and the action exerted by the drug aprepitant on BC cells is currently unknown. We show the involvement of this system in human BC cell lines: i) these cells express mRNA for the NK-1 receptor; ii) they overexpress NK-1 receptors; iii) the NK-1 receptor is involved in their viability; iv) SP induces their proliferation; v) NK-1 receptor antagonists block SP-induced mitogen stimulation of these cells; vi) the specific antitumor action of such antagonists on these cells occurs through the NK-1 receptor; and vii) BC cell death is due to apoptosis. We also found NK-1 receptors and SP in all human BC samples studied. The NK-1 receptor may be a promising target in the treatment of BC and NK-1 receptor antagonists could be candidates as a new antitumor drug in the treatment of BC.
View Figures
View References

Related Articles

Journal Cover

October 2014
Volume 45 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Muñoz, M., González-Ortega, A., Salinas-Martín, M.V., Carranza, A., Garcia-Recio, S., Almendro, V., & Coveñas, R. (2014). The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer. International Journal of Oncology, 45, 1658-1672. https://doi.org/10.3892/ijo.2014.2565
MLA
Muñoz, M., González-Ortega, A., Salinas-Martín, M. V., Carranza, A., Garcia-Recio, S., Almendro, V., Coveñas, R."The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer". International Journal of Oncology 45.4 (2014): 1658-1672.
Chicago
Muñoz, M., González-Ortega, A., Salinas-Martín, M. V., Carranza, A., Garcia-Recio, S., Almendro, V., Coveñas, R."The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer". International Journal of Oncology 45, no. 4 (2014): 1658-1672. https://doi.org/10.3892/ijo.2014.2565